Latest Placebo-controlled study Stories
SYDNEY, May 23, 2011 /PRNewswire/ -- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel(R) for the treatment of bacterial vaginosis (BV). Key Points: VivaGel(R) meets primary endpoint, demonstrating significant efficacy for treatment of BVVivaGel(R) expected to avoid many shortcomings of existing therapiesTrial results support new patent filing which extends VivaGel(R) protection...
ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee. The randomized, double-blind, placebo-controlled Phase II study will evaluate the safety and efficacy of...
(Ivanhoe Newswire) -- Pirfenidone reduces the rate of decline of lung function in patients with idiopathic pulmonary fibrosis- a condition that affects hundreds of thousands os people worldwide and will eventually kill four out of five people.In this study, patients were either given pirfenidone of a placebo for a minimum of 72 weeks. The researchers assessed the change in percentage predicted forced vital capacity (FVC) at week 72.The study showed an 8.4% decline in mean FVC in the...
BRISBANE, Calif., May 13, 2011 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a rare and fatal lung disease affecting more than...
Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue LUND, Sweden, April 19 /PRNewswire/ - NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM )cremophor-free IV cyclosporine formulation is used...
SILVER SPRING, Md., March 21, 2011 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011. FREEDOM-C(2) is a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study of a sustained release oral formulation of treprostinil diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients receiving an endothelin receptor antagonist and/or a...
MALVERN, Pa., March 9, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX(® )for the treatment of Peyronie's disease. In accordance with the study design, all enrolled patients will have received their first injection of either XIAFLEX or placebo by the end of March 2011. The Company will exceed its enrollment...
Treatment has implications for US veterans returning home from warA new University of Colorado Boulder study indicates an ancient form of complementary medicine may be effective in helping to treat people with mild traumatic brain injury, a finding that may have implications for some U.S. war veterans returning home.The study involved a treatment known as acupressure in which one's fingertips are used to stimulate particular points on a person's body -- points similar to those stimulated with...
SYDNEY, Feb. 18, 2011 /PRNewswire/ -- Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) announced today that there has been an agreement for strategy and design of the Phase III clinical registration trial for the CVac(TM) immunotherapy therapeutic ovarian cancer vaccine. The agreement comes after the European regulator, the European Medicines Agency (EMA) advised that Scientific Advice for the Phase III trial had successfully been granted. Receiving Scientific Advice is a...
WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA). Regorafenib is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities. "This is an important step in the overall...
